enmetazobactam

beta-lactamase inhibitor

Also Known As:

(2S,3S,5R)-3-methyl-3-((3-methyltriazol-3-ium-1-yl)methyl)-4,4,7-trioxo-4'6-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate; 1H-1,2,3-triazolium, 3-(((2S,3S,5R)-2-carboxy-3-methyl-4,4-dioxido-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-3-yl)methyl)-1-methyl-, inner salt; AAI101; GLXC-25798

Networked: 19 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Knechtle, Philipp: 6 articles (01/2021 - 01/2019)
2.	Belley, Adam: 4 articles (01/2021 - 01/2019)
3.	Shapiro, Stuart: 4 articles (01/2021 - 01/2019)
4.	Franzoni, Samantha: 3 articles (12/2020 - 01/2020)
5.	Hsueh, Po-Ren: 2 articles (10/2022 - 01/2022)
6.	Ko, Wen-Chien: 2 articles (10/2022 - 01/2022)
7.	Lee, Wen-Sen: 2 articles (10/2022 - 01/2022)
8.	Lu, Min-Chi: 2 articles (10/2022 - 01/2022)
9.	Bassetti, Matteo: 2 articles (12/2021 - 12/2020)
10.	Vena, Antonio: 2 articles (12/2021 - 12/2020)

Related Diseases

1.	Infections 01/01/2020 - "This study examined pharmacokinetic-pharmacodynamic (PK-PD) relationships of enmetazobactam, in combination with cefepime, for ESBL-producing isolates of Klebsiella pneumoniae in 26-h murine neutropenic thigh infection models. " 01/01/2020 - "Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined with Cefepime in a Neutropenic Murine Thigh Infection Model." 01/01/2019 - "AAI101 paired with cefepime, also a zwitterion, is in phase III of clinical development for the treatment of serious Gram-negative infections. " 08/18/2015 - "Addition of AAI101 restored the activity of cefepime such that the MIC50 was reduced from >64 mg/L for cefepime to 0.13 mg/L for cefepime/AAI101, supporting its continued development treatment for infections caused by these organisms. " 05/01/2015 - "Against a panel of 20 mostly carbapenemase-producing cefepime-nonsusceptible strains of the family Enterobacteriaceae, we evaluated the MICs of cefepime in the presence of various fixed AAI101 concentrations (1, 2, 4, 8, and 16 mg/liter) and the in vivo efficacy of simulated human doses of cefepime and cefepime-AAI101 in a neutropenic murine thigh infection model. "
2.	Sepsis (Septicemia) 01/01/2019 - "Notably, the in vivo efficacy of cefepime-AAI101 was demonstrated using a mouse septicemia model, indicating the ability of AAI101 to bolster significantly the therapeutic efficacy of cefepime in vivo The combination of AAI101 with cefepime represents a potential carbapenem-sparing treatment regimen for infections suspected to be caused by Enterobacteriaceae expressing ESBLs." 01/01/2022 - "Multicenter surveillance of in vitro activities of cefepime-zidebactam, cefepime-enmetazobactam, omadacycline, eravacycline, and comparator antibiotics against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii complex causing bloodstream infection in Taiwan, 2020." 10/01/2022 - "In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018-2020."
3.	Urinary Tract Infections (Urinary Tract Infection) 01/01/2019 - "The combination of enmetazobactam with cefepime has entered clinical trials to assess safety and efficacy in patients with complicated urinary tract infections. " 10/04/2022 - "Cefepime/Enmetazobactam for Complicated Urinary Tract Infections." 01/01/2019 - "The combination of enmetazobactam and cefepime has entered phase 3 development in patients with complicated urinary tract infections. " 01/01/2020 - "Cefepime-enmetazobactam has been investigated in a phase 3 trial in patients with complicated urinary tract infections or acute pyelonephritis. " 01/01/2023 - "Cefepime/Enmetazobactam vs Piperacillin/Tazobactam and Complicated Urinary Tract Infection or Acute Pyelonephritis-Reply."
4.	Pyelonephritis 10/04/2022 - "Further research is needed to determine the potential role for cefepime/enmetazobactam in the treatment of complicated UTI and pyelonephritis. " 01/01/2020 - "Cefepime-enmetazobactam has been investigated in a phase 3 trial in patients with complicated urinary tract infections or acute pyelonephritis. " 01/01/2023 - "In complicated UTI or pyelonephritis, cefepime-enmetazobactam increased success vs. piperacillin-tazobactam at 14 d." 10/04/2022 - "Among patients with complicated UTI or acute pyelonephritis caused by gram-negative pathogens, cefepime/enmetazobactam, compared with piperacillin/tazobactam, met criteria for noninferiority as well as superiority with respect to the primary outcome of clinical cure and microbiological eradication. " 01/01/2023 - "Cefepime/Enmetazobactam vs Piperacillin/Tazobactam and Complicated Urinary Tract Infection or Acute Pyelonephritis-Reply."
5.	Healthcare-Associated Pneumonia 12/16/2020 - "This result provides a rationale to further consider cefepime-enmetazobactam for the treatment of nosocomial pneumonia caused by multidrug-resistant Enterobacteriaceae." 12/16/2020 - "Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia." 01/01/2020 - "These data and analyses provide the underpinning evidence for the combined use of cefepime and enmetazobactam for nosocomial pneumonia." 12/16/2020 - "An understanding of the extent of partitioning of β-lactam-β-lactamase inhibitor combinations into the human lung is required to better understand the potential role of cefepime-enmetazobactam for the treatment of nosocomial pneumonia. "

Related Drugs and Biologics

1.	Cefepime (Maxipime)
2.	Carbapenems (Carbapenem Antibiotics)
3.	carbapenemase
4.	Tazobactam Drug Combination Piperacillin (Zosyn)
5.	taniborbactam
6.	cefepime-zidebactam
7.	Lactams
8.	eravacycline
9.	omadacycline
10.	Aztreonam

Related Therapies and Procedures

1.	Therapeutics